Open Access
Open access
International Journal of Molecular Sciences, volume 22, issue 24, pages 13405

Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors

Publication typeJournal Article
Publication date2021-12-14
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor5.6
ISSN16616596, 14220067
Catalysis
Organic Chemistry
Inorganic Chemistry
Physical and Theoretical Chemistry
Computer Science Applications
Spectroscopy
Molecular Biology
General Medicine
Abstract

Combination therapy is becoming imperative for the treatment of many cancers, as it provides a higher chance of avoiding drug resistance and tumor recurrence. Among the resistance-conferring factors, the tumor microenvironment plays a major role, and therefore, represents a viable target for adjuvant therapeutic agents. Thus, hypoxia and extracellular acidosis are known to select for the most aggressive and resilient phenotypes and build poorly responsive regions of the tumor mass. Carbonic anhydrase (CA, EC 4.2.1.1) IX isoform is a surficial zinc metalloenzyme that is proven to play a central role in regulating intra and extracellular pH, as well as modulating invasion and metastasis processes. With its strong association and distribution in various tumor tissues and well-known druggability, this protein holds great promise as a target to pharmacologically interfere with the tumor microenvironment by using drug combination regimens. In the present review, we summarized recent publications revealing the potential of CA IX inhibitors to intensify cancer chemotherapy and overcome drug resistance in preclinical settings.

Citations by journals

1
2
3
Cancers
Cancers, 3, 14.29%
Cancers
3 publications, 14.29%
Molecules
Molecules, 2, 9.52%
Molecules
2 publications, 9.52%
Journal of Enzyme Inhibition and Medicinal Chemistry
Journal of Enzyme Inhibition and Medicinal Chemistry, 2, 9.52%
Journal of Enzyme Inhibition and Medicinal Chemistry
2 publications, 9.52%
Archiv der Pharmazie
Archiv der Pharmazie, 2, 9.52%
Archiv der Pharmazie
2 publications, 9.52%
Pharmaceuticals
Pharmaceuticals, 1, 4.76%
Pharmaceuticals
1 publication, 4.76%
Biomedicines
Biomedicines, 1, 4.76%
Biomedicines
1 publication, 4.76%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 1, 4.76%
International Journal of Molecular Sciences
1 publication, 4.76%
Scientific Reports
Scientific Reports, 1, 4.76%
Scientific Reports
1 publication, 4.76%
Sensors and Actuators, B: Chemical
Sensors and Actuators, B: Chemical, 1, 4.76%
Sensors and Actuators, B: Chemical
1 publication, 4.76%
Journal of Personalized Medicine
Journal of Personalized Medicine, 1, 4.76%
Journal of Personalized Medicine
1 publication, 4.76%
Cancer Medicine
Cancer Medicine, 1, 4.76%
Cancer Medicine
1 publication, 4.76%
Expert Opinion on Therapeutic Targets
Expert Opinion on Therapeutic Targets, 1, 4.76%
Expert Opinion on Therapeutic Targets
1 publication, 4.76%
Advanced Functional Materials
Advanced Functional Materials, 1, 4.76%
Advanced Functional Materials
1 publication, 4.76%
Steroids
Steroids, 1, 4.76%
Steroids
1 publication, 4.76%
Materials Advances
Materials Advances, 1, 4.76%
Materials Advances
1 publication, 4.76%
1
2
3

Citations by publishers

1
2
3
4
5
6
7
8
9
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 9, 42.86%
Multidisciplinary Digital Publishing Institute (MDPI)
9 publications, 42.86%
Wiley
Wiley, 4, 19.05%
Wiley
4 publications, 19.05%
Taylor & Francis
Taylor & Francis, 3, 14.29%
Taylor & Francis
3 publications, 14.29%
Elsevier
Elsevier, 2, 9.52%
Elsevier
2 publications, 9.52%
Springer Nature
Springer Nature, 1, 4.76%
Springer Nature
1 publication, 4.76%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 1, 4.76%
Royal Society of Chemistry (RSC)
1 publication, 4.76%
1
2
3
4
5
6
7
8
9
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Kalinin S. et al. Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors // International Journal of Molecular Sciences. 2021. Vol. 22. No. 24. p. 13405.
GOST all authors (up to 50) Copy
Kalinin S., Malkova A., Sharonova T., Sharoyko V., Bunev A. S., T Supuran C., Krasavin M. Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors // International Journal of Molecular Sciences. 2021. Vol. 22. No. 24. p. 13405.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/ijms222413405
UR - https://doi.org/10.3390%2Fijms222413405
TI - Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors
T2 - International Journal of Molecular Sciences
AU - Malkova, Anna
AU - Sharonova, Tatiana
AU - Kalinin, Stanislav
AU - Sharoyko, Vladimir
AU - Bunev, Alexander S.
AU - T Supuran, Claudiu
AU - Krasavin, Mikhail
PY - 2021
DA - 2021/12/14 00:00:00
PB - Multidisciplinary Digital Publishing Institute (MDPI)
SP - 13405
IS - 24
VL - 22
PMID - 34948200
SN - 1661-6596
SN - 1422-0067
ER -
BibTex |
Cite this
BibTex Copy
@article{2021_Kalinin,
author = {Anna Malkova and Tatiana Sharonova and Stanislav Kalinin and Vladimir Sharoyko and Alexander S. Bunev and Claudiu T Supuran and Mikhail Krasavin},
title = {Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors},
journal = {International Journal of Molecular Sciences},
year = {2021},
volume = {22},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
month = {dec},
url = {https://doi.org/10.3390%2Fijms222413405},
number = {24},
pages = {13405},
doi = {10.3390/ijms222413405}
}
MLA
Cite this
MLA Copy
Kalinin, Stanislav, et al. “Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors.” International Journal of Molecular Sciences, vol. 22, no. 24, Dec. 2021, p. 13405. https://doi.org/10.3390%2Fijms222413405.
Found error?